{
  "hash": "e9045c1874057849e22f080b227d3546",
  "result": {
    "engine": "knitr",
    "markdown": "---\ntitle: \"Pharmacokinetics\"\nsubtitle: \"Dose-Exposure\"\ndate: last-modified\n---\n\n> \"What the body does to the drug\"\n\n## Executive summary\n\n**Pharmacokinetics (PK)** asks a single question:  \n\n> *“Given an input (dose & regimen), what exposure (concentration-time profile) will the body create?”*\n\nThis page is your quick-reference for that mapping. It is organised as follows:\n\n| Section | What you get | Key take-aways |\n|---------|--------------|----------------|\n| **Therapeutic window** | Where efficacy ⇢ safety overlap | Target *C~min~* and *C~max~* |\n| **Single-dose kinetics** | IV bolus + oral equations | How *V~d~* and *k~e~* shape curves |\n| **Repeated/continuous input** | Multiple-dose & infusion profiles | Why accumulation ratio (*R~ac~*) matters |\n| **Equations at a glance** | One-liner table of canonical PK formulae | Copy-paste cheatsheet |\n| **Deep dives** | Absorption · Distribution · Elimination | Mechanistic levers behind each parameter |\n\nUse the overview to **choose the right regimen**, then jump to the deep-dive pages when you need mechanism-level detail.\n\n## Key symbols and canonical equations\n\n| Symbol | Description |\n| :----: | :---------- |\n| $\\D$ | Dose |\n| $\\ii$ | Dosing interval (interdose interval) |\n| $\\CL$ | Clearance |\n| $\\Vd$ | Volume of distribution |\n| $\\ke$ | Elimination rate constant |\n| $\\ka$ | Absorption rate constant |\n| $\\F$ | Bioavailability |\n| $\\Rin$ | Infusion rate |\n| $T_\\text{inf}$ | Duration of infusion |\n| $\\Cpl$ | Plasma concentration |\n| $\\mathrm{R_ac}$ | Accumulation ratio |\n\n: Pharmacokinetic symbols {#tbl-pk-symbols tbl-colwidths=\"[20, 80]\"}\n\n### Clearance (CL)\n\n$$\n\\CL = \\frac{\\D \\times \\F}{\\AUCinf} \\;=\\; \\ke \\times \\Vd\n$$ {#eq-cl-1cmt}\n\n## Therapeutic window\n\n\n::: {.cell layout-align=\"center\"}\n\n```{.r .cell-code}\ntibble::tibble(\n  time = c(0, 0.5, 1, 2, 4, 6, 8, 12), # h\n  conc = c(0, 14, 12, 9, 6, 4, 3, 0) # mg/L (example)\n) |>\n  ggplot2::ggplot(ggplot2::aes(time, conc)) +\n  ggplot2::annotate(\n    # shaded window\n    \"rect\",\n    xmin = -Inf,\n    xmax = Inf,\n    ymin = 3,\n    ymax = 10,\n    alpha = 0.08,\n    fill = \"forestgreen\"\n  ) +\n  ggplot2::geom_line(linewidth = 1) +\n  ggplot2::geom_hline(yintercept = 3, linetype = \"dashed\") + # MEC\n  ggplot2::geom_hline(yintercept = 10, linetype = \"dashed\") + # MTC\n  ggplot2::labs(\n    x = \"Time (h)\",\n    y = \"Concentration (mg/L)\"\n  ) +\n  ggplot2::annotate(\n    # labels\n    \"text\",\n    x = 11.5,\n    y = 10.4,\n    hjust = 1,\n    label = \"Safety threshold\",\n    size = 3\n  ) +\n  ggplot2::annotate(\n    \"text\",\n    x = 11.5,\n    y = 3.4,\n    hjust = 1,\n    label = \"Efficacy threshold\",\n    size = 3\n  ) +\n  ggplot2::theme_minimal()\n```\n\n::: {.cell-output-display}\n![Concentration–time profile and the therapeutic window.](index_files/figure-html/fig-therapeutic-window-1.png){#fig-therapeutic-window fig-align='center' width=864}\n:::\n:::\n\n\n## Single-dose kinetics\n\n### Intravenous bolus\n\n#### Single i.v. dose\n\nInitial concentration @eq-c0-iv.\n\n$$\n\\C_0 = \\frac{\\D}{\\Vd}\n$$ {#eq-c0-iv}\n\nPlasma concentration @eq-c-single-iv-dose-1cmt.\n\n$$\n\\C(t) = \\C_0 \\times e^{-\\ke \\times t}\n$$ {#eq-c-single-iv-dose-1cmt}\n\n#### Multiple i.v. doses\n\n$$\n\\C_n(t) =\n  \\frac{\\D}{\\Vd} \\times\n  \\frac{\n    \\left(1 - e^{-n \\times \\ke \\times \\ii}\\right)\n  }{\n    \\left(1 - e^{-\\ke \\times \\ii}\\right)\n  } \\times\n  e^{-\\ke \\times t}\n$$\n\nat peak: $t = 0$; at steady state $\\mathrm{n} \\rightarrow \\infty$; at trough: $t = \\ii$\n\n$$\n\\C_\\text{max, ss} =\n  \\frac{\\D}{\\V} \\times\n  \\frac{1}{\\left(1 - e^{-\\ke \\ii} \\right)}\n$$ {#eq-cmaxss-multiple-iv-dose-1cmt}\n\n$$\n\\C_\\text{min, ss} = \\C_\\text{max, ss} \\times e^{-\\ke \\times \\ii}\n$$ {#eq-cminss-multiple-iv-dose-1cmt}\n\nPlasma concentration @eq-c-multiple-iv-dose-1cmt.\n\n$$\n\\C(t) = \\Cmax \\times e^{-\\ke \\times t}\n$$ {#eq-c-multiple-iv-dose-1cmt}\n\nPeak @eq-cmax-multiple-iv-dose-1cmt.\n\n$$\n\\Cmax =\n  \\frac{\n    \\C_0\n  }{\n    1 - e^{-\\ke \\times \\ii}\n  }\n$$ {#eq-cmax-multiple-iv-dose-1cmt}\n\nTrough @eq-cmin-multiple-iv-dose-1cmt.\n\n$$\n\\Cmin = \\Cmax \\times e^{-\\ke \\times \\ii}\n$$ {#eq-cmin-multiple-iv-dose-1cmt}\n\nAverage concentration (steady state) @eq-cavgss-multiple-iv-dose-1cmt.\n\n$$\n\\bar{\\C}_\\text{pl, ss} = \\frac{\\D}{\\CL \\times \\ii}\n$$ {#eq-cavgss-multiple-iv-dose-1cmt}\n\n### Oral administration\n\n#### Single p.o. dose\n\nPlasma concentration @eq-c-single-po-dose-1cmt.\n\n$$\n\\C =\n  \\frac{\n    \\F \\times \\D \\times \\ka\n  }{\n    \\Vd \\left(\\ka - \\ke \\right)\n  }\n  \\left(\n    e^{-\\ke \\times t} - e^{-\\ka \\times t}\n  \\right)\n$$ {#eq-c-single-po-dose-1cmt}\n\nTime of maximum concentration @eq-tmax-single-po-dose-1cmt.\n\n$$\nt_\\text{max} =\n  \\frac{\n    \\ln \\left(\\ka / \\ke \\right)\n  }{\n    \\ka - \\ke\n  }\n$$ {#eq-tmax-single-po-dose-1cmt}\n\n#### Multiple p.o. doses\n\nPlasma concentration @eq-c-multiple-po-dose-1cmt.\n\n$$\n\\C =\n\\frac{\n  \\F \\times \\D \\times \\ka\n}{\n  \\Vd (\\ka - \\ke)\n}\n\\left(\n  \\frac{\n    e^{-\\ke \\times t}\n  }{\n    1 - e^{-\\ke \\times \\ii}\n  } -\n  \\frac{\n    e^{-\\ka \\times t}\n  }{\n    1 - e^{-\\ka \\times \\ii}\n  }\n\\right)\n$$ {#eq-c-multiple-po-dose-1cmt}\n\nTime of maximum concentration @eq-tmax-multiple-po-dose-1cmt.\n\n$$\nt_\\text{max} =\n  \\frac{\n    \\ln\n      \\left(\n        \\frac{\n          \\ka \\times \\left(1 - e^{-\\ke \\times \\ii} \\right)\n        }{\n          \\ke \\times \\left(1 - e^{-\\ka \\times \\ii} \\right)\n        }\n      \\right)\n  }{\n    \\left(\\ka - \\ke\\right)\n  }\n$$ {#eq-tmax-multiple-po-dose-1cmt}\n\nAverage concentration (steady state) @eq-cavgss-multiple-po-dose-1cmt.\n\n$$\n\\bar{\\C} =\n  \\frac{\n    \\F \\times \\D\n  }{\n    \\CL \\times \\ii\n  }\n$$ {#eq-cavgss-multiple-po-dose-1cmt}\n\n### Intravenous infusion\n\n$$\n\\Rin = \\frac{\\D}{T}\n$$\n\nPlasma concentration (steady state) @eq-css-ctsinf-1cmt\n\n$$\n\\Cplss = \\frac{\\Rin}{\\CL}\n$$ {#eq-css-ctsinf-1cmt}\n\nPlasma concentration (during infusion) @eq-c-ctsinf-1cmt\n\n$$\n\\C(t) = \\frac{\\Rin}{\\CL}\n\\left(\n  1 - e^{-\\ke \\times t}\n\\right)\n$$ {#eq-c-ctsinf-1cmt}\n\nCalculated clearance (Chiou equation) @eq-cl-ctsinf-chiou\n\n$$\n\\CL =\n  \\frac{2 \\Rin}{\\left(\\C_1 + \\C_2 \\right)} +\n  \\frac{\n    2 \\Vd \\left(\\C_1 - \\C_2 \\right)\n  }{\n    \\left(\\C_1 + \\C_2 \\right) \\left(t_2 - t_1 \\right)\n  }\n$$ {#eq-cl-ctsinf-chiou}\n\n### Single infusion\n\nSince $\\ii = t$ for $\\Cmax$\n\nPeak @eq-cmax-single-infusion-1cmt\n\n$$\n\\Cmax = \\frac{\\Rin}{\\CL} \\left(1 -e ^{-\\ke T} \\right)\n$$ {#eq-cmax-single-infusion-1cmt}\n\nTrough @eq-cmin-single-infusion-1cmt\n\n$$\n\\Cmin = \\Cmax \\times e^{-\\ke (\\ii - T)}\n$$ {#eq-cmin-single-infusion-1cmt}\n\n#### Multiple infusions\n\nPeak @eq-cmax-multiple-infusion-1cmt.\n\n$$\n\\Cmax =\n  \\frac{\\Rin}{\\CL} \\times\n  \\frac{\n    \\left(1 - e^{-\\ke \\times T} \\right)\n  }{\n    \\left(1 - e^{-\\ke \\times \\ii} \\right)\n  }\n$$ {#eq-cmax-multiple-infusion-1cmt}\n\nTrough @eq-cmin-multiple-infusion-1cmt.\n\n$$\n\\Cmin =\n  \\Cmax \\times e^{-\\ke (\\ii - T)}\n$$ {#eq-cmin-multiple-infusion-1cmt}\n\n#### Calculated parameters\n\nCalculated elimination rate constant (1-compartment case) @eq-ke-1cmt.  \nWith C^\\*^~max~ = measured peak and C^\\*^min = measured trough, measured over the time interval $\\Delta t$\n$$\n\\ke =\n  \\frac{\n    \\ln \\left(\\frac{\\Cmax^*}{\\Cmin^*} \\right)\n  }{\n    \\Delta t\n  }\n$$ {#eq-ke-1cmt}\n\nCalculated peak @eq-cmax-calc-multiple-infusion-1cmt.  \nWith C^\\*^~max~ = measured peak, measured at time t^\\*^ after the end of the infusion\n\n$$\n\\Cmax = \\frac{\\Cmax^*}{e^{-\\ke t^*}}\n$$ {#eq-cmax-calc-multiple-infusion-1cmt}\n\nCalculated trough @eq-cmin-calc-multiple-infusion-1cmt.  \nWith C^\\*^min = measured trough, measured at time t^\\*^ before the start of the next infusion\n\n$$\n\\Cmin = \\Cmin^* \\times e^{-\\ke \\times t^*}\n$$ {#eq-cmin-calc-multiple-infusion-1cmt}\n\nCalculated volume of distribution @eq-vd-calc-multiple-infusion-1cmt.\n\n$$\n\\Vd =\n  \\frac{\\Rin}{\\ke}\n  \\times\n  \\frac{\n    \\left(1 - e^{-\\ke \\times T}\\right)\n  }{\n    \\left[\n      \\Cmax - \\left(\\Cmin \\times e^{-\\ke \\times T} \\right)\n    \\right]\n  }\n$$ {#eq-vd-calc-multiple-infusion-1cmt}\n\nCalculated recommended dosing interval for infusion start @eq-ii-calc-multiple-infusion-1cmt.\n\n$$\n\\ii =\n  \\frac{\n    \\ln\n    \\left(\n      \\frac{\n        \\C_\\text{max, desired}\n      }{\n        \\C_\\text{min, desired}\n      }\n    \\right)\n  }{\n    \\ke\n  } + T\n$$ {#eq-ii-calc-multiple-infusion-1cmt}\n\nCalculated recommended dose @eq-dose-calc-multiple-infusion-1cmt.\n\n$$\n\\D =\n  \\C_\\text{max, desired} \\times \\ke \\times \\V \\times T\n  \\frac{\n    \\left(1 - e^{-\\ke \\ii}\\right)\n  }{\n    \\left(1 - e^{-\\ke T} \\right)\n  }\n$$ {#eq-dose-calc-multiple-infusion-1cmt}\n\n## Multiple-dose kinetics\n\n## Two-compartment PK model\n\n$$\n\\C = a \\times e^{-\\alpha t} + b \\times e^{-\\rho t}\n$$ {#eq-c-2cmt}\n\n$$\n\\AUCinf = a / \\alpha + b / \\beta\n$$ {#eq-auc-2cmt}\n\n$$\n\\V_\\text{d, area} > \\V_\\text{ss} > \\V_\\text{c}\n$$ {#eq-v-2cmt}\n\nVd_area = V beta?\n\n## Dosage regimens\n\n$$\n\\C_\\text{inf} = \\C_\\text{ss} \\times \\left(1 - e^{-\\ke t}\\right)\n$$\n(1-compartment)\n\n$$\n\\C_\\text{ss, avg} = \\F \\times \\D /(\\CL \\times \\ii)\n$$\n(variation of eq. 24)\n\n$$\n\\mathrm{R_ac} = 1 / \\left(1 - e^{-\\ke \\ii}\\right)\n$$\n(1-compartment)\n\n$$\n\\C_\\text{ss, max} = \\F \\times \\D \\times \\mathrm{R_ac} / \\V\n$$\n(1-compartment)\n\n$$\n\\C_\\text{ss, min} =\n  \\C_\\text{ss, max} \\times e^{-k \\times \\ii}\n$$\n(1-compartment, combination of eq. 22 and 28)\n\n$$\n\\ii_\\text{max} =\n  \\ln\n    \\left(\n      \\C_\\text{ss, max} / \\C_\\text{ss, min}\n    \\right) / \\ke\n$$\n(1-compartment, variation of eq. 23)\n\n$$\n\\text{Corresponding dose} \\times \\F =\n  \\V \\times\\left(\\C_\\text{max, ss} - \\C_\\text{min, ss}\\right)\n$$\n(1-compartment)\n\n### Exposure (AUC)\n\n$$\n\\AUC_\\text{iv} =\n  \\C_0 / \\ke\n$$\n(1-compartment)\n\n$$\n\\AUC_\\text{iv} =\n  \\C_1 / \\lambda_1 + \\C_2 / \\lambda_2\n$$\n(2-compartment)\n\n$$\n\\AUC =\n  \\Sigma(\\text{trapezoids}) +\n  \\C_\\text{last} / \\ke\n$$\n(Always applicable)\n\n## Things that can affect PK\n\n### Sex\n\nCommon covariate.\nMales and females have different genetic physiological composition that are similar within the groups.\nThus, \"sex\" is really a surrogate covariate for genetic and physiological variability.\n\nFemales have ~15% lower kidney function than males.\nMetabolism by CYP3A is not expected to differ between sexes.\n\nThis does **not** include **pregnant women**, which can have different physiological processes.\n\n### Age\n\nAge is a common covariate in PK because body composition and physiology change over time.\n\nChildren differ substantially from adults in terms of physiology.\nDuring late adolescence, physiological changes stabilize, but gradual alterations continue throughout adulthood.\n\nIn most adult patients, dose adjustments based on age are not necessary, as their age is typically close to that of the \"typical\" patient used for dose selection.\nHowever, adjustment may be warranted when the patient’s age deviates by more than 20 years from the typical reference age.\n\nAs adults age, organ function declines, especially renal function.\nThis is reflected in commonly used kidney function equations, many of which include age as a predictor.\n\n* **Kidney function decreases by approximately 1% per year in adults.**\n* Metabolic clearance also tends to decline with age.\n\nTherefore, including age as a covariate on drug clearance is always a sensible choice.\n\n### Weight\n\n#### Ideal Body Weight\n\n##### Male\n\nIBW = 50 kg + 2.3 kg for each inch over 5ft in height\n\n##### Female\n\nIBW = 45.5 kg + 2.3 kg for each inch over 5ft in height\n\n##### Obese\n\nABW = IBW + 0.4 * (TBW-IBW)\n\n### Disease\n\n### Genetics\n\n#### Race\n\nThe [FDA guidance](https://www.fda.gov/media/75453/download) defines race and ethnicity as \"not anthropologically or scientifically-based designations, but categories that described the sociocultural construct of our society\" --- originally devised by the Office of Management and Budget for US population classification.\n\nObserved pharmacokinetic and pharmacodynamic differences between racial groups more likely reflect socioeconomic disparities, environmental risk factors, and genetic variation in drug-metabolizing enzymes --- not race per se.\nRace is, by definition, a subjective and imperfect proxy for these underlying determinants.\n\nDespite this, race retains pragmatic value in drug development.\nBiDil --- approved specifically for self-identified African Americans with heart failure --- illustrates this: a broad-population trial failed, but a subgroup analysis in Black patients led to a dedicated trial confirming efficacy.\nCardiovascular drugs also generally show attenuated effects in Black patients, occasionally informing alternative dosing in labeling and clinical practice.\n\nCYP2D6 poor metabolizer prevalence differs substantially across African, Asian, and European populations.\nSince genotyping and phenotyping remain uncommon in drug development, race --- despite its imprecision --- captures more metabolic variation than no stratification at all.\n\n### DDI\n",
    "supporting": [
      "index_files"
    ],
    "filters": [
      "rmarkdown/pagebreak.lua"
    ],
    "includes": {},
    "engineDependencies": {},
    "preserve": {},
    "postProcess": true
  }
}